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KDM1A/LSD1, a histone H3K4/K9 demethylase and epigenetic regulator with roles in both gene activation
and repression, has increased expression in multiple cancer types. Harris et al., in this issue of Cancer
Cell, and Schenk et al. show that KDM1A may be a viable therapeutic target in treating AML.Epigenetic regulation of gene expression,
through both histone modification and
DNA methylation, provides cells with a
heritable mechanism for controlling gene
expression without altering the DNA
nucleotide sequence. KDM1A/lysine spe-
cific demethylase 1 (LSD1) was discov-
ered in 2004 as the first histone deme-
thylase, with specificity for mono- and
dimethyl histone H3 lysine 4 and mono-
and dimethyl histone H3 lysine 9. Prior to
its identification, methylation of histones
was thought to be a relatively permanent
epigenetic mark. KDM1A is a member of
the flavin adenine dinucleotide (FAD)-
dependent family of amine oxidases,
which require FAD to oxidize the mono-
or dimethyl lysine to an imine intermediate
that is further hydrolyzed to unmodified
lysine and formaldehyde (Shi et al., 2004).
KDM1A was originally identified as a
member of the CoREST repressor com-
plex (You et al., 2001) (Figure 1A). When
this complex is targeted to lineage-
specific genes, KDM1A demethylates
the activating H3K4me2 mark to silence
their expression. Additional repressive
complexes containing KDM1A have since
been identified (Wang et al., 2007).
Conversely, KDM1A has been found to
interact with multiple proteins/complexes
that function in geneactivation (Figure 1A).
KDM1A is required for transcription of
androgen receptor (AR) and estrogen
receptor (ER) target genes, where it is
recruited via interaction with AR or ER,
respectively, and is thought to demethy-
late the repressive H3K9me2 mark to
allow for gene activation (Metzger et al.,
2005). KDM1A is also a member of a tran-
scription elongation complex composed
of ELL (elongation factor RNA polymeraseII), pTEFb, AF4, and AFF4 (Biswas et al.,
2011). Additionally, KDM1A is a compo-
nent of an MLL supercomplex associated
with active transcription (Nakamura et al.,
2002). MLL itself is an epigenetic modifier
as a histone methyltransferase with spec-
ificity for H3K4.
In normal hematopoietic development,
hematopoietic stemcells undergo a series
of changes in gene expression which both
promote differentiation to mature blood
cell lineages and repress genes neces-
sary for maintaining stem cell identity.
These changes are mediated, in part, by
epigenetic modifiers such as KDM1A
andMLL (Figure 1B). In leukemia, this nor-
mal process of cellular maturation goes
awry; the leukemic stem cells (LSCs) do
not differentiate appropriately, with resul-
tant accumulation of immature blast cells.
The mixed lineage leukemia gene (MLL)
is frequently involved in chromosomal
translocation with one of a variety of part-
ner genes in acute leukemias of myeloid
(AML) or lymphoid lineage. As a result,
functional oncogenic fusion proteins are
produced that promote the constitutive
expression of MLL target genes, thereby
blocking differentiation and promoting
proliferation of immature blast cells. Re-
cent studies have shown increased
KDM1A expression in AML regardless of
subtype/cytogenetic status (http://www.
proteinatlas.org; Berglund et al., 2008)
as well as in a variety of other tumor types
(Hayami et al., 2011). This raises the
hypothesis that KDM1Amay be an attrac-
tive target for therapeutic development.
One therapeutic approach that has
been successful in treating the acute pro-
myelocytic leukemia (APL) subset of leu-
kemias is forced differentiation of imma-Cancer Celture leukemic cells into mature myeloid
cells. In the majority of APLs, chromo-
somal translocations involving the retinoic
acid receptor alpha gene (RARA) and
the promyelocytic leukemia gene (PML)
produce the PML-RARa fusion protein.
PML-RARa aberrantly interacts with co-
repressor molecules such as NCOR and
HDAC to prevent expression of RAR
target genes necessary for differentiation.
The use of all-trans retinoic acid (ATRA)
can lift the differentiation block by pro-
moting expression of RAR-responsive
genes. However, the ability of ATRA to
promote differentiation of PML-RARa
AML cells is specific to this subset of
leukemia; non-APL AML, such as AML
harboring a MLL translocation, requires
other treatment modalities.
In this issue of Cancer Cell, Harris et al.
(2012) used microarray data from murine
models of MLL leukemia to determine
a correlation between KDM1A expression
level and the leukemia colony-forming
ability, often used as a surrogate assay
to quantify LSC potential. Using both
shRNAs and pharmacological inhibitors
synthesized to target the enzymatic
activity of KDM1A, the authors show that
inhibition of KDM1A results in induction
of differentiation in both murine and pri-
mary human MLL-fusion cells (Figure 1C).
Cells without active KDM1A were unable
to form colonies (indicative of loss of
LSC potential), exhibited differentiated
cell morphology and could not cause
leukemia when introduced into mice.
Gene expression analysis suggested
that KDM1A is responsible for promoting
the oncogenic gene program associated
with MLL-AF9 leukemia. KDM1A co-
localized to genes bound by MLL-AF9,l 21, April 17, 2012 ª2012 Elsevier Inc. 451
Figure 1. KDM1A/LSD1Maintains a Balance in Gene Expression through Activating and RepressiveMechanisms that Are Disrupted in Acute
Myeloid Leukemia
(A and B) In normal cells, KDM1A activates or represses genes through its histone demethylase activity (A), maintaining the balance between hematopoietic stem
cells and differentiation to mature myeloid cells (B).
(C) In AML, increased KDM1A expression promotes an oncogenic gene expression program, causing a block in differentiation associated with increased
H3K4me3 to H3K4me2 ratio at the promoter of target genes. Inhibition of KDM1A restores this balance, promoting blast cell differentiation.
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with a decreased ratio of H3K4me2 to
H3K4me3 on these target genes. Upon
inhibition of KDM1A, no global changes
in H3K4me2 were evident, but the genes
targeted byMLL-AF9 showed an increase
in the H3K4me2 mark at their promoter
and 50 gene regions. This regional in-
crease in H3K4me2 marks increased the
ratio of H3K4me2 to H3K4me3 at the
locus, making the prevalence of themarks
more equal.
Complementary findings were recently
reported in Nature Medicine (Schenk
et al., 2012). The authors examined the
effect of combining ATRA differentiation
therapy with KDM1A inhibition in AML
cells. They found that KDM1A inhibition,
in combination with ATRA therapy, could
sensitize otherwise ATRA-insensitive
cells toward differentiation. This caused452 Cancer Cell 21, April 17, 2012 ª2012 Elsdecreased leukemia-initiating activity
(i.e., engraftment) as well as decreased
tumor burden in human xenograft models.
These combination-treated cells demon-
strated increased expression of genes
associated with myeloid-lineage differ-
entiation and a concomitant increase in
H3K4me2 at their promoters.
Together, these two studies illustrate
the importance of KDM1A in maintaining
expression of oncogenic gene programs
and blocking differentiation in multiple
subtypes of AML and highlight the poten-
tial therapeutic implications of targeting
this important epigenetic regulator in leu-
kemia. Despite these exciting findings,
some very important questions remain
to be addressed. First, what is the mech-
anism by which KDM1A functions at
these target genes in AML? The presence
of KDM1A at MLL-AF9 target genesevier Inc.decreases the H3K4me2 to H3K4me3
ratio, but how does KDM1A demethyla-
tion of H3K4me2/me1 lead to an increase
in H3K4me3? Additionally, what proteins/
protein complexes are recruited to these
loci when KDM1A is present? Finally,
what will be the long-term effect on nor-
mal hematopoietic stem cells and hema-
topoietic cell homeostasis and differ-
entiation programs when treated with
KDM1A inhibitors? Harris et al. (2012)
start to address this question in their
article. They found that while the overall
frequency of colony forming cells remains
the same upon KDM1A inhibition, ery-
throid lineage differentiation is decreased.
In mice, this manifested as lethal anemia.
How will these in vitro and in vivo re-
sults translate to patients that may be
treated long-term with KDM1A inhibitors?
Although the questions are plentiful in this
Cancer Cell
Previewsemerging field of targeting epigenetic re-
gulators in cancer, the results presented
in these articles highlight the potential of
using such therapies, not only in AML,
but perhaps in other cancers that are
dependent on aberrant epigenetic activity
for survival.
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TLX1 and TLX3 are two closely-related homeobox transcriptional repressors frequently misexpressed and
translocated in T cell acute lymphoblastic leukemia (T-ALL). In this issue of Cancer Cell, Dadi et al. provide
new insights into how these factors are recruited by ETS-1 to the TCRa enhancer and actively repress differ-
entiation.In the majority of human cancers, tumor
cells tend to share aspects of their identity
with a corresponding cell of origin, a prop-
erty that has proved useful for diagnosis
in the clinic and provided researchers
with a wide range of potential therapeutic
targets. In particular, acute lymphoblastic
leukemia (ALL) often presents as a snap-
shot of lymphocyte differentiation, based
on surfacemarker expression and charac-
teristic molecular genetic signatures
(Aifantis et al., 2008). A large amount of
data over the last decade has underlined
the connection between physiological
lymphocyte differentiation and the trans-
formation events that lead to ALL.
Whole-genome profiling and sequencing
studies have suggested that some of the
most common mutational targets in ALL
are also key regulators of normal differen-
tiation, including IKZF1andPAX5 inB-ALL
and NOTCH1 and GATA3 in T cell ALL(T-ALL) (Mullighan and Downing, 2009).
Such findings have suggested that certain
oncogenic lesions have the ability to
‘‘freeze’’ cellular differentiation at distinct
stages. Therefore, a thorough under-
standing of how oncogenes halt develop-
mental processes will provide clues
toward the reinforcement of differentiation
and, presumably, the desired outcomesof
cell cycle exit and/or programmed cell
death. In this issue of Cancer Cell, Dadi
et al. (2012) reveal how two such onco-
genes (TLX1 and TLX3) manage to inter-
fere with a critical stage of T cell differenti-
ation, leading to development of a subset
of T-ALL.
T cell differentiation and ALL are
ideal models to study such oncogenic
effects due to our detailed knowledge on
the phenotypic and molecular programs
of differentiation. T cells mature in the
thymus following a highly orchestratedprocess, controlled by cell intrinsic (tran-
scription factors) and cell extrinsic
(antigen, cytokines, and chemokines)
factors. Uncommitted, multipotent pro-
genitors enter the thymus through the
cortico-medullary junction, sense Notch
ligands, and initiate commitment to the
T cell lineage. At this point the T cell
receptor (TCR) b, g, and d loci become
accessible and the outcome of rearrange-
ment leads to either the differentiation
toward the gd lineage or (as it happens
with the vast majority of T cells) the
expression of the pre-TCR, which helps
drive cellular proliferation and leads to
the CD4+8+ stage. At this stage, the
TCRa locus undergoes recombination
which leads to the surface expression
of a TCRab and subsequent selection
events (Sleckman et al., 1998). RAG-
mediated rearrangement of the TCRa
locus is a process controlled by distinctl 21, April 17, 2012 ª2012 Elsevier Inc. 453
